COMPANY PRESENTATION

We Laser your World



Industrial and Medical Laser Solutions

DISCLAIMER

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



AGENDA



1 - Key Highlights

A Primary Player Providing Medical, Industrial, and Conservation Laser Solutions Worldwide



Hi-Tech company

Hi-Tech industrial group active in opto-electronics with proprietary technologies and know how developed over 35 years



International Group

More than 20 companies active worldwide on several markets and application segments. Listed on the Milan Stock Exchange, Star segment



Among the leaders in the global market

Progressively widening its worldwide presence registered continuous growth over the years



Worldwide distribution network

1,093 employees worldwide, more than 40,000 laser sources sold

Constant Growth



13% Revenue CAGR 2011 – 2016

40% EBIT CAGR 2011 - 2016




THE LASER WORLD

Light Amplification by Stimulated

Emission of Radiation











EL.EN. MILESTONES



1981	2000	2002 2004	2005	2007	2016
Established in Florence	IDO		Cynosure listed on the Nasdaq	WH Penta Chutia established in in PRC	n Exit from Cynosure
199	98		20	006	2014
Smart	epil		Smar	tlipo	Monalisa 7

EL.EN. WORLDWIDE




BUSINESS LINES

El.En. designs, manufactures ad sells worldwide:

MEDICAL laser devices – INDUSTRIAL laser solutions – laser systems for CONSERVATION of the cultural heritage








STRONG R&D ACTIVITY

- Driven by constant research and development, El.En. is committed to producing advanced laser devices - excellent in terms of performance, value for money, reliability, respect for the environment and post-sale service
- Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser-tissue interaction:
 - Broadening Mona Lisa Touch Clinical studies
 - New Pico second laser platform
 - Clinical studies on cutaneous ulcers
 - Painless laser hair removal
 - Development of a body contouring platform
 - Increased power of RF laser sources
 - Innovative applications for mid power laser systems
 - High power metal cutting laser systems

A PATH OF GROWTH



- Constant growth driven by strong execution and favorable market conditions
- 2016 EBITDA margin 12,8% and EBIT margin 10,9%

STRATEGIC STRENGTHS

Multidisciplinary And Multifacility R&D Activity: Sources – Systems - Applications

INDUSTRIAL

Combine High tech laser source development with flexible production facilities focusing on applications

MEDICAL

Technological and clinical innovation improving performances and broadening the application scope of our laser systems

- √ New applications
- ✓ Improved efficacy and effectiveness of current applications

Leverage worldwide distribution with multi brand approach

2- Market Trends & Growth Opportunities

MEDICAL & AESTHETIC LASER MARKET

Consumers spending billions to restore, repair and refresh their body

- U.S. market for non-surgical cosmetic procedures totalled \$5bn in 2014; worldwide, roughly 24 million non-surgical cosmetic procedures were performed in 2013
- Non-invasive fat reduction was fastest-growing nonsurgical procedure in 2014

Source: World Health Organization, ASAPS

Key growth drivers:

- Increasingly aging population
- Increase in healthcare spending
- Requirements for quick and less invasive surgical interventions

THE MEDICAL LASER MARKET

Global market for medical lasers by end use, through 2019 (\$ millions)

Market Segment	2014	2019	CAGR% 2014-2019
Surgical	813	1.219	8,4%
Cosmetic	1.024	2.097	15,4%
Dental	244	623	20,7%
Veterinary	115	247	16,5%
Total	2.195	4.185	13,8%

Source: BCC research

SURGICAL LASER SYSTEMS AND MEDICAL APPLICATIONS





AESTHETIC APPLICATIONS AND SYSTEMS



Quanta System Q1







DISCOVERY PICO

Quanta System Q1

MEDIOSTAR



MOTUS AX





THE INDUSTRIAL LASER MARKET

Global market and forecast for high power laser systems, by application (by value)

By Value		CAGR	(%)	
	2016	2020	2013-2016	2016-2020
Cutting	3.014	3.965	7,8	7,1
Welding and Brazing	1.605	2.231	8,7	8,6
Surface treatment and Other	63	86	8,3	8,1
Total	4.682	6.282	8,1	7,6

Source: Optech Consulting

INDUSTRIAL LASERS APPLICATIONS

AUTOMOTIVE, LABELING, DIGITAL CONVERTING, PACKAGING, EASY OPENING, DECORATION












RF177

INDUSTRIAL CO2 LASER SOURCES















3- Financial Highlights

INCOME STATEMENT 2016

Euro Million	31/12/2015	%	31/12/2016	%	Var.%
	- , ,	-	unaudited	-	
Revenues	217.670	100,0%	252.646	100,0%	16,1%
Gross margin	96.318	44,2%	110.533	43,8%	14,8%
EBITDA	25.666	11,8%	32.388	12,8%	26,2%
EBIT	21.499	9,9%	27.594	10,9%	28,4%
Pretax Income	23.113	10,6%	52.721	20,9%	128,1%
Net income	14.371	6,6%	40.408	16,0%	181,2%
Net Income per share	0,74		2,09		


BALANCE SHEET 2016

Euro Million	31/12/2015	31/12/2016	Var.%
		unaudited	
Total non current assets	97.766	64.737	-33,8%
Net Working Capital	59.861	54.160	-9,5%
Net financial position	29.815	82.784	177,7%
Long term liabilities	7.904	8.982	13,6%
Net Equity	179.539	192.699	7,3%
Net capital employed	149.724	109.915	-26,6%
Net Working Capital on sales	28%	21%	
ROCE	14%	25%	
(EBIT/Net capital employed)			
Capex	8.243	11.441	

Proposed divend €0,40




REVENUE BREAKDOWN




in Euro million

MEDICAL LASERS BUSINESS REVENUE




INDUSTRIAL LASERS BUSINESS REVENUE



- 2017 Guidance

2017 GUIDANCE




5- Appendix

INVESTMENT OPPORTUNITY

- Taking advantage of Positive Market Dynamics
 - ✓ Increasing exposure to the growing medical and aesthetic segments
 - Established presence in emerging markets
- Leading technology platforms Cutting-edge content and technology driven by culture of innovation
- Stable shareholder base and solid cash position to fund growth

EL.EN. STOCK PERFORMANCE



EL.EN. MULTIPLES

Stockholder's Equity per share	9
Price / Book Value Adj.	2,8
EV /EBIT (85% EBIT)	17,8
EV / Sales (85% Sales)	1,9

El.En. Market Cap.	510,4 @	€ 26,45
Net financial position	82,8 @	31/12/2016
Financial investments m/l term	10,9 @	31/12/2016
Enterprise Value	416,8	

EL.EN. COMPARABLES

Dec. 31st, 2016 Medical/Aesthetic	Price	Revenue	Var.% Revenue	EBIT	EBIT %	МК.Сар.	EV	EV/Sales	EV/EBIT	P/E	P/Book Value
Syneron	\$10,40	\$298.102	7%	\$3.228	1%	\$357.560	\$271.139	0,9	84,0	1997,5	1,7
Zeltiq	\$55,64	\$354.201	39%	\$13.224	4%	\$2.240.000	\$2.181.621	6,2	165,0	3227,7	16,3
Cutera	\$20,85	\$118.056	25%	\$2.397	2%	\$295.480	\$241.406	2,0	100,7	114,7	4,8
Biolase	\$1,20	\$51.810	7%	\$(14.962)	-29%	\$86.020	\$76.845	1,5	n.a.	n.a.	3,9
Cynosure	\$65,97	\$433.532	28%	\$27.340	6%	\$1.610.000	\$1.391.790	3,2	50,9	113,4	3,5
Industrial											
IPG Photonics Co.	\$120,29	\$1.006.173	12%	\$364.313	36%	\$6.440.000	\$5.612.554	5,6	15,4	24,7	4,1
Prima Industrie	€ 21,60	€ 393.886	8%	€ 18.528	5%	€ 226.440	\$310.655	0,8	16,8	22,3	1,6
El.En. (1)	€ 26,45	€ 252.646	16%	€ 27.594	11%	€ 510.418	\$416.753	1,9	17,8	12,6 28,5 (*)	2,8

⁽¹⁾ EV and multiplies as for previous slide

^(*) w/o one time income


STRONG M&A ACTIVITY IN OUR SPACE

- ✓ Cohrent (COHR) acquired Rofin-Sinar (RSTI) in 2016 (equity value \$942m)
- ✓ Hologic acquired Cynosure (CYNO), closing pending (equity value \$1.65 bn)
- ✓ Allergan bought Zeltiq (ZLTQ), closing pending (equity value \$2.48bn)

NEW FACTORY IN SAMARATE



...AND IN WENZHOU (PRC)



...LASER CHINA IN SHANGHAI (PRC)



CONTACTS

El.En. SPA

Enrico ROMAGNOLI Investor Relations Manager tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR

Financial Communication, IR and Press Office

Bianca FERSINI MASTELLONI - <u>b.fersini@polytemshir.it</u>

<u>s.dagostino@polytemshir.it</u>; <u>s.marongiu@polytemshir.it</u>

Tel. +39 06-69923324

